LLY

NYSE

ELI LILLY & Co

Health Care, Pharmaceuticals

$1,185.71

close 7 Aug 2026

+86.66%

52-week change

$1.12T

market cap

$625.90

$1,249.45

52-week range

Valuation

Market cap$1.12T

P/E (TTM / 5y avg)39.79x67.71x

Forward P/E (FY2026 / FY2027)32.75x25.68x

PEG (TTM / fwd)0.811.19

P/S (TTM)14.01x

P/B32.95x

EV/EBITDA (TTM)32.52x

FCF yield (TTM)1.63%

Cash flow & dividend

FCF (TTM)$18.19B

FCF per share (TTM)$19.32

FCF margin (TTM)22.83%

Dividend yield (indicated / 5y avg)0.58%0.91%

Annualized dividend$6.92

Payout ratio (EPS / FCF)21.66%31.80%

Growth & quality

Revenue YoY, latest Q+47.67%

Diluted EPS YoY, latest Q+26.23%

Operating margin (TTM)—

Net margin (TTM)33.53%

ROE (latest FY)77.78%

Net debt / EBITDA (TTM)1.29

Interest coverage (TTM)—

Price

+348.78%+35.16%/yrover 5y

Weekly closes · split-adjusted

close 7 Aug 2026

Fundamentals

Fiscal years, last 10, CAGR chips on growth series, plus a dimmed trailing-twelve-month bar

Revenue

5Y CAGR +21.58%10Y CAGR +12.56%

Diluted EPS

5Y CAGR +27.58%10Y CAGR +26.09%

FCF per share

5Y CAGR +12.23%10Y CAGR +18.80%

Operating cash flow

5Y CAGR +20.93%10Y CAGR +18.95%

Free cash flow

5Y CAGR +11.91%10Y CAGR +16.80%

Dividends per share

5Y CAGR +15.24%10Y CAGR +11.61%

Payout ratio

FCF payout ratio

FCF margin

Return on equity

Shares outstanding

5Y CAGR -0.28%10Y CAGR -1.68%

Net debt / EBITDA

Earnings

Street estimates, not SEC filings

Next / Q3 FY26

Date29 Oct 2026

EPS estimate$9.52

Revenue estimate$21.94B

Last reported

Date—

EPS——

Revenue——